Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048


News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Roche : Glaxo Names Roche Veteran as Research Head

share with twitter share with LinkedIn share with facebook
share via e-mail
11/08/2017 | 01:53pm EDT
By Noemie Bisserbe and Jonathan D. Rockoff 

GlaxoSmithKline PLC said it appointed Hal Barron as its next chief scientific officer, snagging one of the pharmaceutical industry's leading research luminaries to bolster its flagging drug pipeline.

Dr. Barron made his name researching, and then managing research teams, at biotech trailblazer Genentech. Investors were impressed by the hire, sending shares up 1.45% in London trading.

He will replace Patrick Vallance, who is leaving Glaxo in March to take up a role as chief scientific advisor to the U.K. government. Since taking the reins at Glaxo in April, Chief Executive Emma Walmsley has promised to boost the company's research and development.

She has faced critical investors and analysts, who have said that the company has shifted emphasis from risky but high-growth prescription drugs over recent years, while pushing deeper into the slower-growing but stable vaccine and consumer-healthcare businesses. Ms. Walmsley took over as CEO after serving as head of consumer healthcare at Glaxo, raising questions about whether she had the interest in and experience to revive Glaxo's pharmaceuticals business.

Ms. Walmsley has narrowed the focus of Glaxo's research and said she would focus resources on the company's biggest opportunities. It now falls to Dr. Barron to help her determine what avenues might turn into blockbusters years from now.

It is the latest in a string of high-profile hires by Ms. Walmsley. In September, she brought aboard former AstraZeneca PLC executive Luke Miels as head of Glaxo's pharmaceuticals division. She also hired Karenann Terrell, previously Wal-Mart Stores Inc. chief information officer, as GSK's chief digital and technology officer.

Dr. Barron's appointment "marks another in a list of strong hires" for Ms. Walmsley, wrote Bank of America Merrill Lynch analysts in a note to clients.

Dr. Barron is coming from the research team at Calico, a pharmaceuticals venture backed by Google parent Alphabet Inc. A cardiologist by training, he landed as a researcher at Genentech, whose labs were celebrated for the discovery of a string of biotech drugs, including blockbuster cancer treatment Herceptin.

During a succession of management roles at Genentech, and at Roche Holding AG, which eventually bought it, Dr. Barron oversaw the development of breast-cancer therapy Kadcyla and skin-cancer drug Zelboraf.

More recently, he served as research chief at Calico's anti-aging drug start-up. There, he had reunited with former Genentech research chief Arthur Levinson, Calico's founder and chief executive.

Dr. Barron will remain based in San Francisco, not at Glaxo headquarters in London, the company said.

At Glaxo, Dr. Barron will need to turn around laboratories that have dealt with some notable disappointments, including Darapladib, a heart drug it hoped would become a multibillion-dollar blockbuster, and MAGE-A3, an experimental treatment for lung cancer.

Since taking over, Ms. Walmsley has axed more than 30 drug-research projects to focus on four key disease areas. The company plans to pour more investment into 16 drug candidates that it believes stand the best chance of becoming big sellers, while shelving 13 drug-development programs and around 20 early-stage research projects.

Write to Noemie Bisserbe at noemie.bisserbe@wsj.com and Jonathan D. Rockoff at Jonathan.Rockoff@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
GLAXOSMITHKLINE -0.21% 1646.4 Delayed Quote.10.41%
ROCHE HOLDING LTD. -2.42% 264.65 Delayed Quote.11.42%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ROCHE HOLDING LTD.
07/18Novartis raises full-year targets, aims to settle U.S. lawsuit
07/18Novartis raises full-year targets, aims to settle U.S. lawsuit
07/16Abbott to hike production of lower-cost glucose monitors as diabetes soars
07/12EUROPE : Swiss stocks keep a lid on European shares as pharma drag lingers
07/11EUROPE : European shares dip on pharma drag as Fed optimism sizzles out
07/09GENENTECH : Presents a Broad Range of Data for Hemlibra (Emicizumab-kxwh) Demons..
07/09Roche presents a broad range of data for Hemlibra demonstrating continued ben..
07/08European shares dip on Deutsche Bank, fading hopes of sharp Fed cut
07/08SPARK THERAPEUTICS : Roche, Spark push back takeover deadline in $4.3 billion de..
07/03GENENTECH : Announces Positive Results for First Global Phase III Study Investig..
More news
Financials (CHF)
Sales 2019 60 696 M
EBIT 2019 22 027 M
Net income 2019 14 090 M
Debt 2019 2 214 M
Yield 2019 3,46%
P/E ratio 2019 16,2x
P/E ratio 2020 16,1x
EV / Sales2019 3,76x
EV / Sales2020 3,66x
Capitalization 226 B
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 289,59  CHF
Last Close Price 264,65  CHF
Spread / Highest target 34,5%
Spread / Average Target 9,42%
Spread / Lowest Target -24,4%
EPS Revisions
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.11.42%230 263
JOHNSON & JOHNSON2.34%345 980
PFIZER-1.35%237 451
ROCHE HOLDING13.37%230 263
NOVARTIS24.46%216 273